文献速递前列腺癌

超分割与常规分割全盆腔放疗在前列腺癌中的随机临床试验

Ultrahypofractionated Versus Conventionally Fractionated Whole-pelvis Radiotherapy in Prostate Cancer: A Randomized Clinical Trial.
PubMed 文献 · Eur Urol Oncol · 2026-01-03

HOPE 是一项 2 期多中心随机试验,比较超分割(UH)与常规分割(CF)全盆腔放疗(WPRT)的毒性和患者报告结局。

要点

  • UH-WPRT 在 1 年肠道功能上非劣于 CF-WPRT(p=0.0016 非劣效)。
  • 两组 1 年 EPIC 泌尿子域评分无显著差异。
  • UH 组 1 例 3 级泌尿毒性,CF 组无晚期 3-5 级毒性。

核心结论

  • 在联合前列腺高剂量率近距离放疗推量时,UH-WPRT 的耐受性与 CF-WPRT 相当。

研究设计与样本

  • HOPE 为 2 期、多机构、非盲、随机临床试验,比较 UH-WPRT 与 CF-WPRT 的毒性和患者报告结局。
  • CF-WPRT 组 39 例,UH-WPRT 组 41 例,中位随访 3.34 年。

主要发现

  • 放疗后 1 年,EPIC 肠道功能评分均值(±标准差)CF 组为 88.4 ± 12.1,UH 组为 90.6 ± 11.1,非劣效检验 p=0.0016。
  • EPIC 肠道总评分均值(±标准差)CF 组 86.7 ± 14.2,UH 组 89.0 ± 12.3,p=0.24。
  • EPIC 肠道困扰评分均值(±标准差)CF 组 85.0 ± 18.0,UH 组 87.4 ± 16.3,p=0.28。
  • 1 年时两组 EPIC 泌尿子域评分无显著差异。
  • CF 组无晚期(>6 周)3-5 级泌尿生殖或胃肠道毒性,UH 组 1 例发生 3 级泌尿生殖毒性。

临床怎么用

  • 对于计划接受高剂量率近距离放疗推量的不利中危/高危/极高危前列腺癌患者,可考虑使用 UH-WPRT 替代 CF-WPRT。
  • UH-WPRT 的肠道和泌尿毒性在 1 年时与 CF-WPRT 相当,支持其作为可耐受的治疗选择。

局限性

  • 数据尚不成熟,不足以评估肿瘤学终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The role of ultrahypofractionated (UH) whole-pelvis radiotherapy (WPRT) as an alternative to conventionally fractionated (CF) WPRT is not well defined. METHODS: HOPE is a phase 2, multi-institutional, unblinded, randomized clinical trial designed to compare toxicity and patient-reported outcomes between UH-WPRT and CF-WPRT using the Expanded Prostate Cancer Index Composite (EPIC-50) questionnaire at 1 yr after treatment. Eighty patients with unfavorable intermediate-risk, high-risk, or very high-risk disease for whom high-dose-rate prostate brachytherapy was planned were randomly assigned 1:1 to either CF-WPRT or UH-WPRT. KEY FINDINGS AND LIMITATIONS: Baseline clinical characteristics were similar for the CF-WPRT (39 patients) and UH-WPRT (41 patients) arms. All patients received treatment according to their randomization allocation. Median follow-up was 3.34 yr. At 1 yr after radiotherapy, the mean (± standard deviation) EPIC bowel function score was noninferior between the CF-WPRT and UH-WPRT arms (88.4 ± 12.1 vs 90.6 ± 11.1; p = 0.0016 for noninferiority). Similarly, the mean EPIC bowel total score (86.7 ± 14.2 vs 89.0 ± 12.3; p = 0.24) and bother score (85.0 ± 18.0 vs 87.4 ± 16.3; p = 0.28) did not significantly differ between the arms. No significant differences in EPIC urinary subdomains at 1 yr were observed between the arms. No late (>6 wk) grade 3-5 genitourinary or gastrointestinal toxicities were reported in the CF-WPRT arm, while one patient in the UH-WPRT arm experienced grade 3 genitourinary toxicity. The data are not yet mature enough for evaluation of oncological endpoints. CONCLUSIONS AND CLINICAL IMPLICATIONS: Results from the HOPE trial demonstrate that UH-WPRT is as well tolerated as CF-WPRT when combined with a high-dose-rate brachytherapy boost to the prostate.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mendez LC, Crook J, Martell K, et al. Ultrahypofractionated Versus Conventionally Fractionated Whole-pelvis Radiotherapy in Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. 2026. PMID: 41486040. doi:10.1016/j.euo.2025.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。